tocris small molecule library Search Results


93
Tocris molecules tocriscreen stem cell toolbox tocris
KEY RESOURCES TABLE
Molecules Tocriscreen Stem Cell Toolbox Tocris, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecules tocriscreen stem cell toolbox tocris/product/Tocris
Average 93 stars, based on 1 article reviews
molecules tocriscreen stem cell toolbox tocris - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

96
Tocris molecules chir99021
KEY RESOURCES TABLE
Molecules Chir99021, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecules chir99021/product/Tocris
Average 96 stars, based on 1 article reviews
molecules chir99021 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

90
Tocris small-molecule controls
KEY RESOURCES TABLE
Small Molecule Controls, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small-molecule controls/product/Tocris
Average 90 stars, based on 1 article reviews
small-molecule controls - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris small molecule tyrosine kinase inhibitor zm323881 hydrochloride
Increased VEGF-A production in suspension conditions by VEGFR2 OVCAR-3 knockdown cells. (a) ELISA for VEGF-A (Mean ± SEM) detected no change in the amount of VEGF produced by the three OVCAR-3 transfected constructs growing in adhesive monolayer culture. The middle graph shows a significant increase in the production of VEGF-A by shRNAKDR1 clones growing in suspension and the bottom graph shows a significant increase in VEGF-A production by spheroids formed from shRNAKDR1 cells compared shRNAKDR5 and shKDRGAPDH. (b) Short term blockade of VEGFR2 signaling in OVCAR-3 cells with pharmacological inhibitor <t>ZM323881</t> lead to reduced expression of VEGFR2, NRP-1 and VEGF. (c) Proliferation assay using AlamarBlue (Mean ± SEM) demonstrates significant cell growth in shRNAKDR1 cells compared to other clones. (d) Upper panel shows ascites (OVCAR-3 cells) collected from the intraperitoneal cavity of mice; bottom panel shows western blot of collected cells, demonstrating the stability of VEGFR2 knockdown in the recovered ascites cells. (e) ELISA results (Mean ± SEM) showing higher VEGF-A production in shRNAKDR1 ascites supernatant and lysed cells recovered from intraperitoneal cavities of injected mice, compared to samples from other stable lines.
Small Molecule Tyrosine Kinase Inhibitor Zm323881 Hydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small molecule tyrosine kinase inhibitor zm323881 hydrochloride/product/Tocris
Average 90 stars, based on 1 article reviews
small molecule tyrosine kinase inhibitor zm323881 hydrochloride - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris s)-(+)-dimethindene maleate
Increased VEGF-A production in suspension conditions by VEGFR2 OVCAR-3 knockdown cells. (a) ELISA for VEGF-A (Mean ± SEM) detected no change in the amount of VEGF produced by the three OVCAR-3 transfected constructs growing in adhesive monolayer culture. The middle graph shows a significant increase in the production of VEGF-A by shRNAKDR1 clones growing in suspension and the bottom graph shows a significant increase in VEGF-A production by spheroids formed from shRNAKDR1 cells compared shRNAKDR5 and shKDRGAPDH. (b) Short term blockade of VEGFR2 signaling in OVCAR-3 cells with pharmacological inhibitor <t>ZM323881</t> lead to reduced expression of VEGFR2, NRP-1 and VEGF. (c) Proliferation assay using AlamarBlue (Mean ± SEM) demonstrates significant cell growth in shRNAKDR1 cells compared to other clones. (d) Upper panel shows ascites (OVCAR-3 cells) collected from the intraperitoneal cavity of mice; bottom panel shows western blot of collected cells, demonstrating the stability of VEGFR2 knockdown in the recovered ascites cells. (e) ELISA results (Mean ± SEM) showing higher VEGF-A production in shRNAKDR1 ascites supernatant and lysed cells recovered from intraperitoneal cavities of injected mice, compared to samples from other stable lines.
S) (+) Dimethindene Maleate, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s)-(+)-dimethindene maleate/product/Tocris
Average 90 stars, based on 1 article reviews
s)-(+)-dimethindene maleate - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris total drug screen library
Increased VEGF-A production in suspension conditions by VEGFR2 OVCAR-3 knockdown cells. (a) ELISA for VEGF-A (Mean ± SEM) detected no change in the amount of VEGF produced by the three OVCAR-3 transfected constructs growing in adhesive monolayer culture. The middle graph shows a significant increase in the production of VEGF-A by shRNAKDR1 clones growing in suspension and the bottom graph shows a significant increase in VEGF-A production by spheroids formed from shRNAKDR1 cells compared shRNAKDR5 and shKDRGAPDH. (b) Short term blockade of VEGFR2 signaling in OVCAR-3 cells with pharmacological inhibitor <t>ZM323881</t> lead to reduced expression of VEGFR2, NRP-1 and VEGF. (c) Proliferation assay using AlamarBlue (Mean ± SEM) demonstrates significant cell growth in shRNAKDR1 cells compared to other clones. (d) Upper panel shows ascites (OVCAR-3 cells) collected from the intraperitoneal cavity of mice; bottom panel shows western blot of collected cells, demonstrating the stability of VEGFR2 knockdown in the recovered ascites cells. (e) ELISA results (Mean ± SEM) showing higher VEGF-A production in shRNAKDR1 ascites supernatant and lysed cells recovered from intraperitoneal cavities of injected mice, compared to samples from other stable lines.
Total Drug Screen Library, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total drug screen library/product/Tocris
Average 90 stars, based on 1 article reviews
total drug screen library - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris pd0325901
Increased VEGF-A production in suspension conditions by VEGFR2 OVCAR-3 knockdown cells. (a) ELISA for VEGF-A (Mean ± SEM) detected no change in the amount of VEGF produced by the three OVCAR-3 transfected constructs growing in adhesive monolayer culture. The middle graph shows a significant increase in the production of VEGF-A by shRNAKDR1 clones growing in suspension and the bottom graph shows a significant increase in VEGF-A production by spheroids formed from shRNAKDR1 cells compared shRNAKDR5 and shKDRGAPDH. (b) Short term blockade of VEGFR2 signaling in OVCAR-3 cells with pharmacological inhibitor <t>ZM323881</t> lead to reduced expression of VEGFR2, NRP-1 and VEGF. (c) Proliferation assay using AlamarBlue (Mean ± SEM) demonstrates significant cell growth in shRNAKDR1 cells compared to other clones. (d) Upper panel shows ascites (OVCAR-3 cells) collected from the intraperitoneal cavity of mice; bottom panel shows western blot of collected cells, demonstrating the stability of VEGFR2 knockdown in the recovered ascites cells. (e) ELISA results (Mean ± SEM) showing higher VEGF-A production in shRNAKDR1 ascites supernatant and lysed cells recovered from intraperitoneal cavities of injected mice, compared to samples from other stable lines.
Pd0325901, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd0325901/product/Tocris
Average 90 stars, based on 1 article reviews
pd0325901 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris small-molecule inhibitor sb431542
Increased VEGF-A production in suspension conditions by VEGFR2 OVCAR-3 knockdown cells. (a) ELISA for VEGF-A (Mean ± SEM) detected no change in the amount of VEGF produced by the three OVCAR-3 transfected constructs growing in adhesive monolayer culture. The middle graph shows a significant increase in the production of VEGF-A by shRNAKDR1 clones growing in suspension and the bottom graph shows a significant increase in VEGF-A production by spheroids formed from shRNAKDR1 cells compared shRNAKDR5 and shKDRGAPDH. (b) Short term blockade of VEGFR2 signaling in OVCAR-3 cells with pharmacological inhibitor <t>ZM323881</t> lead to reduced expression of VEGFR2, NRP-1 and VEGF. (c) Proliferation assay using AlamarBlue (Mean ± SEM) demonstrates significant cell growth in shRNAKDR1 cells compared to other clones. (d) Upper panel shows ascites (OVCAR-3 cells) collected from the intraperitoneal cavity of mice; bottom panel shows western blot of collected cells, demonstrating the stability of VEGFR2 knockdown in the recovered ascites cells. (e) ELISA results (Mean ± SEM) showing higher VEGF-A production in shRNAKDR1 ascites supernatant and lysed cells recovered from intraperitoneal cavities of injected mice, compared to samples from other stable lines.
Small Molecule Inhibitor Sb431542, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small-molecule inhibitor sb431542/product/Tocris
Average 90 stars, based on 1 article reviews
small-molecule inhibitor sb431542 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
Tocris molecule ro
Increased VEGF-A production in suspension conditions by VEGFR2 OVCAR-3 knockdown cells. (a) ELISA for VEGF-A (Mean ± SEM) detected no change in the amount of VEGF produced by the three OVCAR-3 transfected constructs growing in adhesive monolayer culture. The middle graph shows a significant increase in the production of VEGF-A by shRNAKDR1 clones growing in suspension and the bottom graph shows a significant increase in VEGF-A production by spheroids formed from shRNAKDR1 cells compared shRNAKDR5 and shKDRGAPDH. (b) Short term blockade of VEGFR2 signaling in OVCAR-3 cells with pharmacological inhibitor <t>ZM323881</t> lead to reduced expression of VEGFR2, NRP-1 and VEGF. (c) Proliferation assay using AlamarBlue (Mean ± SEM) demonstrates significant cell growth in shRNAKDR1 cells compared to other clones. (d) Upper panel shows ascites (OVCAR-3 cells) collected from the intraperitoneal cavity of mice; bottom panel shows western blot of collected cells, demonstrating the stability of VEGFR2 knockdown in the recovered ascites cells. (e) ELISA results (Mean ± SEM) showing higher VEGF-A production in shRNAKDR1 ascites supernatant and lysed cells recovered from intraperitoneal cavities of injected mice, compared to samples from other stable lines.
Molecule Ro, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecule ro/product/Tocris
Average 94 stars, based on 1 article reviews
molecule ro - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

97
Tocris molecule iwp2
High purity of cardiomyocytes can be obtained under glucose-depleted and fatty acid (with or without T 3 )-supplemented conditions. (A) The schematic for purification and maturation using metabolic selection. Glycogen synthase kinase 3 inhibitor CHIR99021 and Wnt pathway inhibitor <t>IWP2</t> (gray boxes) were added to the differentiation medium on differentiation days 1 and 4, respectively. On differentiation day 10, cells were dissociated and plated on glass cover slips. After 3 days recovery, cells were cultured with metabolic selection medium (No-glucose DMEM medium supplemented with lactate, fatty acid, and fatty acid + T 3 ). On differentiation day 18, cells were collected for patch clamping experiments. On differentiation day 21, cells were collected for other experiments. (B) Representative fluorescence-activated cell sorting (FACS) analyses of cardiac Troponin T expression in the human pluripotent stem cell (hPSC)-derived cells on day 0 with routine culture medium, and on day 8 with metabolic selection medium. In the control group, the isotype control (mouse IgG) was used instead of the primary antibody. (C) Time courses of selection efficiency using the lactate-supplemented condition (red), the fatty acid-supplemented condition (green), and the fatty acid with T 3 -supplemented condition (purple); cells cultured with routine medium (blue) were set up as the control groups ( n = 3). The asterisk means each test group is significantly different from controls, P < 0.01.
Molecule Iwp2, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecule iwp2/product/Tocris
Average 97 stars, based on 1 article reviews
molecule iwp2 - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

93
Tocris molecule ccr4 antagonist c 021 dihydrochloride
High purity of cardiomyocytes can be obtained under glucose-depleted and fatty acid (with or without T 3 )-supplemented conditions. (A) The schematic for purification and maturation using metabolic selection. Glycogen synthase kinase 3 inhibitor CHIR99021 and Wnt pathway inhibitor <t>IWP2</t> (gray boxes) were added to the differentiation medium on differentiation days 1 and 4, respectively. On differentiation day 10, cells were dissociated and plated on glass cover slips. After 3 days recovery, cells were cultured with metabolic selection medium (No-glucose DMEM medium supplemented with lactate, fatty acid, and fatty acid + T 3 ). On differentiation day 18, cells were collected for patch clamping experiments. On differentiation day 21, cells were collected for other experiments. (B) Representative fluorescence-activated cell sorting (FACS) analyses of cardiac Troponin T expression in the human pluripotent stem cell (hPSC)-derived cells on day 0 with routine culture medium, and on day 8 with metabolic selection medium. In the control group, the isotype control (mouse IgG) was used instead of the primary antibody. (C) Time courses of selection efficiency using the lactate-supplemented condition (red), the fatty acid-supplemented condition (green), and the fatty acid with T 3 -supplemented condition (purple); cells cultured with routine medium (blue) were set up as the control groups ( n = 3). The asterisk means each test group is significantly different from controls, P < 0.01.
Molecule Ccr4 Antagonist C 021 Dihydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecule ccr4 antagonist c 021 dihydrochloride/product/Tocris
Average 93 stars, based on 1 article reviews
molecule ccr4 antagonist c 021 dihydrochloride - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

99
Tocris molecules sb431542
High purity of cardiomyocytes can be obtained under glucose-depleted and fatty acid (with or without T 3 )-supplemented conditions. (A) The schematic for purification and maturation using metabolic selection. Glycogen synthase kinase 3 inhibitor CHIR99021 and Wnt pathway inhibitor <t>IWP2</t> (gray boxes) were added to the differentiation medium on differentiation days 1 and 4, respectively. On differentiation day 10, cells were dissociated and plated on glass cover slips. After 3 days recovery, cells were cultured with metabolic selection medium (No-glucose DMEM medium supplemented with lactate, fatty acid, and fatty acid + T 3 ). On differentiation day 18, cells were collected for patch clamping experiments. On differentiation day 21, cells were collected for other experiments. (B) Representative fluorescence-activated cell sorting (FACS) analyses of cardiac Troponin T expression in the human pluripotent stem cell (hPSC)-derived cells on day 0 with routine culture medium, and on day 8 with metabolic selection medium. In the control group, the isotype control (mouse IgG) was used instead of the primary antibody. (C) Time courses of selection efficiency using the lactate-supplemented condition (red), the fatty acid-supplemented condition (green), and the fatty acid with T 3 -supplemented condition (purple); cells cultured with routine medium (blue) were set up as the control groups ( n = 3). The asterisk means each test group is significantly different from controls, P < 0.01.
Molecules Sb431542, supplied by Tocris, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecules sb431542/product/Tocris
Average 99 stars, based on 1 article reviews
molecules sb431542 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Long-Term In Vitro Expansion of Epithelial Stem Cells Enabled by Pharmacological Inhibition of PAK1-ROCK-Myosin II and TGF-β Signaling

doi: 10.1016/j.celrep.2018.09.072

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: A collection of small molecules (Tocriscreen Stem Cell Toolbox, Tocris; ) were diluted in culture medium to the desired concentrations and added to the culture.

Techniques: Virus, Selection, Recombinant, Real-time Polymerase Chain Reaction, Sequencing, Paraffin Section, Staining, Enzyme-linked Immunosorbent Assay, In Vivo, Methylated DNA Immunoprecipitation Sequencing, Cell Culture, Software, DNA Methylation Assay

Increased VEGF-A production in suspension conditions by VEGFR2 OVCAR-3 knockdown cells. (a) ELISA for VEGF-A (Mean ± SEM) detected no change in the amount of VEGF produced by the three OVCAR-3 transfected constructs growing in adhesive monolayer culture. The middle graph shows a significant increase in the production of VEGF-A by shRNAKDR1 clones growing in suspension and the bottom graph shows a significant increase in VEGF-A production by spheroids formed from shRNAKDR1 cells compared shRNAKDR5 and shKDRGAPDH. (b) Short term blockade of VEGFR2 signaling in OVCAR-3 cells with pharmacological inhibitor ZM323881 lead to reduced expression of VEGFR2, NRP-1 and VEGF. (c) Proliferation assay using AlamarBlue (Mean ± SEM) demonstrates significant cell growth in shRNAKDR1 cells compared to other clones. (d) Upper panel shows ascites (OVCAR-3 cells) collected from the intraperitoneal cavity of mice; bottom panel shows western blot of collected cells, demonstrating the stability of VEGFR2 knockdown in the recovered ascites cells. (e) ELISA results (Mean ± SEM) showing higher VEGF-A production in shRNAKDR1 ascites supernatant and lysed cells recovered from intraperitoneal cavities of injected mice, compared to samples from other stable lines.

Journal:

Article Title: Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells

doi: 10.1038/labinvest.2010.52

Figure Lengend Snippet: Increased VEGF-A production in suspension conditions by VEGFR2 OVCAR-3 knockdown cells. (a) ELISA for VEGF-A (Mean ± SEM) detected no change in the amount of VEGF produced by the three OVCAR-3 transfected constructs growing in adhesive monolayer culture. The middle graph shows a significant increase in the production of VEGF-A by shRNAKDR1 clones growing in suspension and the bottom graph shows a significant increase in VEGF-A production by spheroids formed from shRNAKDR1 cells compared shRNAKDR5 and shKDRGAPDH. (b) Short term blockade of VEGFR2 signaling in OVCAR-3 cells with pharmacological inhibitor ZM323881 lead to reduced expression of VEGFR2, NRP-1 and VEGF. (c) Proliferation assay using AlamarBlue (Mean ± SEM) demonstrates significant cell growth in shRNAKDR1 cells compared to other clones. (d) Upper panel shows ascites (OVCAR-3 cells) collected from the intraperitoneal cavity of mice; bottom panel shows western blot of collected cells, demonstrating the stability of VEGFR2 knockdown in the recovered ascites cells. (e) ELISA results (Mean ± SEM) showing higher VEGF-A production in shRNAKDR1 ascites supernatant and lysed cells recovered from intraperitoneal cavities of injected mice, compared to samples from other stable lines.

Article Snippet: For short-term inhibition of VEGFR2 signaling, the small molecule tyrosine kinase inhibitor ZM323881 hydrochloride (Tocris Bioscience, Ellisville, MS, USA) was used as previously reported ( 21 ).

Techniques: Suspension, Knockdown, Enzyme-linked Immunosorbent Assay, Produced, Transfection, Construct, Adhesive, Clone Assay, Expressing, Proliferation Assay, Western Blot, Injection

High purity of cardiomyocytes can be obtained under glucose-depleted and fatty acid (with or without T 3 )-supplemented conditions. (A) The schematic for purification and maturation using metabolic selection. Glycogen synthase kinase 3 inhibitor CHIR99021 and Wnt pathway inhibitor IWP2 (gray boxes) were added to the differentiation medium on differentiation days 1 and 4, respectively. On differentiation day 10, cells were dissociated and plated on glass cover slips. After 3 days recovery, cells were cultured with metabolic selection medium (No-glucose DMEM medium supplemented with lactate, fatty acid, and fatty acid + T 3 ). On differentiation day 18, cells were collected for patch clamping experiments. On differentiation day 21, cells were collected for other experiments. (B) Representative fluorescence-activated cell sorting (FACS) analyses of cardiac Troponin T expression in the human pluripotent stem cell (hPSC)-derived cells on day 0 with routine culture medium, and on day 8 with metabolic selection medium. In the control group, the isotype control (mouse IgG) was used instead of the primary antibody. (C) Time courses of selection efficiency using the lactate-supplemented condition (red), the fatty acid-supplemented condition (green), and the fatty acid with T 3 -supplemented condition (purple); cells cultured with routine medium (blue) were set up as the control groups ( n = 3). The asterisk means each test group is significantly different from controls, P < 0.01.

Journal: Frontiers in Endocrinology

Article Title: Culture in Glucose-Depleted Medium Supplemented with Fatty Acid and 3,3′,5-Triiodo- l -Thyronine Facilitates Purification and Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes

doi: 10.3389/fendo.2017.00253

Figure Lengend Snippet: High purity of cardiomyocytes can be obtained under glucose-depleted and fatty acid (with or without T 3 )-supplemented conditions. (A) The schematic for purification and maturation using metabolic selection. Glycogen synthase kinase 3 inhibitor CHIR99021 and Wnt pathway inhibitor IWP2 (gray boxes) were added to the differentiation medium on differentiation days 1 and 4, respectively. On differentiation day 10, cells were dissociated and plated on glass cover slips. After 3 days recovery, cells were cultured with metabolic selection medium (No-glucose DMEM medium supplemented with lactate, fatty acid, and fatty acid + T 3 ). On differentiation day 18, cells were collected for patch clamping experiments. On differentiation day 21, cells were collected for other experiments. (B) Representative fluorescence-activated cell sorting (FACS) analyses of cardiac Troponin T expression in the human pluripotent stem cell (hPSC)-derived cells on day 0 with routine culture medium, and on day 8 with metabolic selection medium. In the control group, the isotype control (mouse IgG) was used instead of the primary antibody. (C) Time courses of selection efficiency using the lactate-supplemented condition (red), the fatty acid-supplemented condition (green), and the fatty acid with T 3 -supplemented condition (purple); cells cultured with routine medium (blue) were set up as the control groups ( n = 3). The asterisk means each test group is significantly different from controls, P < 0.01.

Article Snippet: Briefly, hPSC were treated with small molecule CHIR99021 (Tocris, 4423, final concentration 10 μM) in the RPMI-BSA medium [RPMI 1640 Medium (HyClone, SH30027.01) supplemented with 213 μg/ml AA2P ( l -ascorbic acid 2-phosphate magnesium) (A8960, Sigma) and 0.1% bovine serum albumin (BSA) (A1470, Sigma)] for 24 h, then were incubated with RPMI-BSA medium for 48 h. On differentiation day 4, cells were treated with the small molecule IWP2 (Tocris, 3533, final concentration 5 μM) in RPMI-BSA medium.

Techniques: Purification, Selection, Cell Culture, Fluorescence, FACS, Expressing, Derivative Assay, Control